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ABSTRACT 
Organophosphorus compounds ascribed to as nerve agents (sarin, soman, tabun, cyclosarin) 
are highly toxic, and are considered to be the most dangerous chemical compounds. All apparently 
share a common mechanism of cholinesterase inhibition and can cause similar svmotoms. The 
. . 
standard therapy, in the case of organophosphorus poisoning, has the prophylactic use of 
reversibly acting AChE inhibitors and antidotal administration of AChE reactivators-oximes. 
Unfortunately, none of these oximes can be regarded as a broad spectrum antidote, ie, effective 
against all nerve agents. While the presently available oximes (pralidoxime, ohidoxime) are not 
considered to be sufficiently effective against nerve agents, especially in the case of soman 
poisoning, the H oximes (HI-6, HLo7) appear to,be very promising antidotes against nerve agents 
because these are able to protect the experimental animals from toxic effects and improve survival 
of animals poisoned with supralethal doses. A lot of research has been pursued on the treatment 
of sarin, soman, and tabun, but cyclosarin was not considered for such a study for a long time. 
Recently, attention of researchers has also turned to cyclosarin because of its potential use as 
a chemical warfare agent. Cyclosarin is highly toxic organophosphorus compound which is 
resistant to conventional oxime therapy. This paper reviews the latest positionof cyclosarin in 
standpoint of medical treatment by various reactivators considering the ability of various oximes, 
HI-6, HS-6, BI-6, and KO33 of their reactivation potency. 
Keywords: Cyclosarin, nerve agent, chemical warfare agent, organophosphorous compounds, 
cholinesterase inhibition, AChE reactivators, antidots, oximes 
1. INTRODUCTION 
The organophosphates (OP) are used in agriculture 
and in veterinary practice. Potential for  exposure 
t o  chemical  warfare nerve  agents  such  as  
sarin (GB; 0-isopropylmethylfluorophosphonate), 
tabun (GA; 0-ethyldimethylamidocyanophosphate), 
soman (GD; 0-pinacolylmethylfluorophosphonate), 
VX (0-ethyl-S-(2-diisopropy1aminoethyl)-methyl- 
- - 
thiophosphonate) and cyclosarin (GF; O-cyclohexyl- 
methylfluorophosphonate) [Structure I] exists on  
the battlefield (eg, Iran-Iraq war, Desert Storm), 
or  in the civilian sector a s  a threat by a terrorist 
group (eg, Tokyo subway incident), or  as an accident 
as part of current demilitarisation efforts. All apparently 
share a common mechanism of cholinesterase inhibition 
and can cause similar symptoms. Because these 
share  th is  mechanism,  exposure  t o  the same 
organophosphate by multiple routes or to multiple 
organophosphates by  multiple rou'tes, can lead to 
serious additive toxicity'. 
T h e  organophosphates  poison insects and 
mammals  primari ly by phosphorylation of the 
acetylcholinesterase enzyme (AChE, E C  3.1.1.7) 
at nerve endings (Structure 11). The  result is a loss 
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Structure I: Nerve agents VX SOMAN 
(salivation, lacrimation, miosis), hypothermia, mild 
tremors, and mouthasmacking (chewing motions), 
lowered motor activity, decreased tail-pinch response, 
and altered neuromuscular function2 (gait changes 
and increased foot splay). Whereas the neuro- 
pathological lesions associated with organophosphates 
poisoning are well characterised, however, there is 
considerable lack of information on their behavioural 
effects, especially after chronic exposure. The 
importance of neurobehavioural studies lies in the 
fact that behaviour is considered as a functional 
end-product of the various sensory, motor, and integrative 
processes occurring in the nervous system. 
StructureII: Phosphorylatiouof the acetylculinesteraseenzyme 
at nerve endings 
of the available AChE so that the effector organ 
becomes overstimulated by the excess acetylcholine 
(ACh) in the nerve ending. The enzyme is critical 
to normal control of nerve impulse transmission 
from nerve fibres to smooth and skeletal muscle 
cells, glandular cells, and autonomic ganglia, as 
well as within the central nervous system. Some 
critical proportion of the tissue enzyme mass must 
be inactivated by phosphorylation before symptoms 
and signs of poisoning become manifest'. 
In animals, generally all cholinesterase inhibitors 
produce autonomic signs of cholinergic overstimulation 
This particular aspect, therefore, requires thorough 
investigation, more so because behavioural changes 
are now being regarded as a standard indicator of 
toxicity in human beings and animals, chronically 
exposed to low concentrations of potential 
neurotoxicants3. Prolonged epileptic seizures in a 
nerve agent casualty will produce profound, irreversible, 
brain damage that, in turn, will result in long-term 
deficits in cognitive function and behaviour. Combined 
prophylaxis and therapy regimen, however, does 
not prevent nerve agent-induced seizures4, although 
the standard therapy in organophosphates poisoning 
consists of atropoine along with an AChE reactivators 
(Structure 111). 
Cyclosarin was not considered for such a study 
for a long time although research on the treatment 
of sarin, soman, and tabun was p u r s ~ e d ~ - ~ .  Recently, 
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Structure 111: Oximes 
attention is also turned to cyclosarin* because of 
its potential use as a nerve agent and its properties 
are given in Table 1. The research interest was 
Table 1. Properties of cyclosarin 
Molecular formula 
Molecular weight 
Freezing point ('C) 
Boiling point ("C) 
Liquid density (20 'C) 
Vapour density 
Vapour pressure (20 "C) 
Volatility (20 "C) ( mg ma) 
Flash point ('C) 
Estimated miosis level 
(mg min m-') 
Median lethal dose 
(mg min m") 
Anticholinesterase potency 
(~150) 
Ageing half-time (h) 
2500 by skin (vapour) or 
350 (liquid): 35 inhaled (man) 
10.100 
further enhanced during Operation Desert Shield 
and Operation Desert Storm with the possibility 
(later confirmed by the UN Special Commission) 
that cyclosarin also a constituent of the Iraqi chemical 
agent inventory 9.10. 
2 .  IN VZTRO REACTIVATION OF 
CYCLOSARIN-INHIBITED AChE 
In vitro reactivation of the AChE is commonly 
used as the screening method for pre-evaluation 
of the new potential AChE reactivators before the 
in vivo experiments" 13. Advantage of the in vitro 
method is the rather quick evaluation of reactivation 
potency of the AChE reactivators within a short 
period. The reactivating efficacy of oximes in vitro 
usually corresponds to their efficacy" in vivo. On 
the other hand, Lucic15, et al .  reported that this 
rule is not always true. They described samples of 
the AChE reactivators, which were without biological 
activity in vitro, however, were potent in vivo. 
An important factor, which can influence reactivation 
of the AChE, is the choice of the suitable animal 
species. Till today, many species of laboratory 
animals (mouse, guinea pig, rabbit, rat, and monkey) 
have been tested as the suitable source of the 
AChE similar to the human AChE16.17. 
*Its combination with another nerve agent, sarin, named GBIGF, has come to the attention of scientists involved in medical 
protection research, since this combined agent was confirmed to be in chemical weapon stockpiles in some countries. 107 
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Human erythrocyte AChE is used as a source 
reported by Dr Worek18 in Germany. It is generally 
considered, that quaternary salts do not penetrate 
blood-brain b a r ~ i e r l ~ . ~ ~ .  However, this general rule 
does not hold good in many cases. Bajgarzl, et al. 
and Kassa" have opined that quaternary pyridinium 
salts can penetrate the blood-brain barrier. Recently, 
SakuradazO, et al. using in vivo rat brain microdialysis 
technique with HPLCIUV demonstrated an ability 
Another factor, which can influence the results 
obtained in reactivation process, is the choice of 
the AChE assay, of which the most common methods 
are colorimetricz3 and potentiostatic t i t r a t i ~ n ~ ' - ~ ~ .  
Research works, which focus on the reactivation 
of cyclosarin inhibited AChE, are not much informative. 
Some of these are aimed at the preparation or 
testing of the new AChE re activator^^'-^^, and others 
aimed at the choice of appropriate  specie^^^.'^. A 
of pralidoxime (2-PAM; 2-hydroxyiminomethyl-l- list of the currently tested reactivators of cyclosarin- 
methylpyridinium chloride) to penetrate the blood- inhibited AChE and conditions of the reactivation 
brain birrierz1.22. process are given in Table 2 
Pralidoxime 
Table 2. List of the  currently tested reactivators of cyclosarin-inhibited AChE a n d  conditions of the  reactivation process 
Human erythrocytes AChE Oxime concentration (30 pM); inhibition time (2 min); Ellman 
reactivation time (0-60 min) 
Oxime 
Rat brain AChE Oxime concentration ( I O ~ ~ - I O ~ ~  M); inhibition time (30 min); Potentiostatic 
reactivation time ( I 0  min) titration 
Rat brain AChE Oxime concentration ( 1 0 ~ ~ - 1 0 ~ '  M); inhibition time (30 min); Potentiostatic 
reactivation time (10 min) titration 
Species 
Human erythrocytes AChE Oxime concentration (10 pM. 100 pM, and 1000 pM); Ellman I inhibition time (10 m ~ n ) ;  reactivation time (0-250 min) 
Rat brain AChE Oxime concentration (10.' M); inhibition time (30 min); Potentiostat~c 
reactivation time ( I 0  min) titration 
Conditions 
Human, guinea-pig, rabbit, Oxime concentration (100 pM); inhibition time (15 min); Ellman 
rat erythrocytes AChE reactivation time (1-10 min) 
Method I References 
Rat brain AChE Oxime concentration (10~~-10~ '  M); inhibition time (30 min); Potentiostatic 
reactivation time (10 min) titration 
Human erythrocytes AChE Oxime concentration (10-30 pM); inhibition time Ellman 
(30 min); reactivation time (5-60 mill) I 
Obidoxime 
~ ~- 
Human erythrocytes AChE concentration (30 pM); inhibition time (2 
reactivation time (0-60 min) 
Rat brain AChE Oxime concentration (10'~-10-' M); inhibition time (30 min); Potentiostatic 
reactivation time (10 min) titration 
Humanerythrocytes AChE Oxime concentration (10 pM, 100 pM and 1000 pM); Ellman 
inhibition time ( I 0  min); reactivation time (0-250 min) 
Rat brain AChE Oxime concentration ( I O . ~ - I O ~ ~  M); inhibition time Potentiostatic 
(30 min); reactivation time ( I 0  min) titration 
Human, guinea-pig, rabbit, Oxime concentration (100 pM); inhibition time (15 min); Ellman 
rat erythrocytes AChE reactivation time (1-10 min) 
Rat bra~n AChE Oxime concentration (10.' M); ~nhibition time (30 min); Potentiostat~c 
reactivation time ( I 0  min) titration 
Human erythrocytes AChE Oxime concentration (10 pM and 30 pM); inhibition time Ellman I (30 min); reactivation time (5-60 min) 

3 .  IN VZVO REACTIVATION OF 
CYCLOSARIN-INHIBITED AChE 
KO05 
KO33 
HS-6 
KO48 
The assessment of the reactivating and therapeutic 
efficacy of oximes in vivo is necessary for estimating 
the benefits of a new antidote in the treatment of 
human poisoning with organophosphorus corn pound^^^. 
The reactivating efficacy is determined by measuring 
AChE activity in different body parts after intoxication 
with cyclosarin. The therapeutic efficacy of oximes 
against supralethal poisoning with cyclosarin is 
determined by the evaluation of the ED,, values. 
3.1 Zn Vivo Reactivation in Rats 
Rat brain AChE 
Rat brain AChE 
Rat brain AChE 
Rat brain AChE 
Kassa. et al. tested reactivatine efficacv of 
., 
obidoxime [ToxogoninO; 1.3-bis-(4-hydroxyimino- 
methylpyridinium)-2-oxa-propane dibromide], 
O x i m  concentration (10"-1e M); inhibition time 
(30 min); reactivation time (10 min) 
Oxim: concentration (10~~-10" M); inhibition time 
(30 min); reactivation time (10 min) 
Oxime concentration (10-'-10" M); inhibition time 
(30 min); reactivation time (10 min) 
Oxime concentration (10"-10" M); inhibition time 
(30 min); reactivation time (10 min) 
pralidoxime, methoxime [MMC-4; 1,l-bis-(4-hydroxy- 
iminomethylpyridinium)methane dibromide], HI-6 
[1-(2-hydroxyiminomethy1pyridinium)-3- 
(4-carbamoylpyridinium)-2-oxa-propane dichloride], 
HLo-7 [1-(2,4-dihydroxyiminomethy1pyridinium)-4- 
(4-carhamoylpyridinium)-2-oxa-propane dibromide] 
and BI-6 [1-(2-hydroxyiminomethylpyridinium)-4- 
(4-carbamoylpyridinium)-but-2-ene dibromide] 
(100 pmollkg) in brain and diaphragm of rats. The 
oxime therapy was administered 5 min before 
intramuscular application of cyclosarin (80 pglkg). 
BI-6 and methoxime were significantly better 
reactivators of cyclosarin-inhibited AChE than 
pralidoxime and obidoxime but not so efficacious 
as HI-6 and HLo-7. The potency of pralidoxime 
and obidoxime to reactivate cyclosarin-inhibited AChE 
in rat diaphragm was very low. In this study, the 
therapeutic efficacy of the same oximes was determined. 
The H-oximes including BI-6 are sufficiently effective 
against supralethal cyclosarin poisoning at doses 
suggested for human beings (approx. 2 9% of their 
LD,, values). Pralidoxime is not able to completely 
protect rats against the supralethal cyclosarin poisoning. 
Obidoxime is able to protect cyclosarin-poisoned 
rats but only at a higher dose than that suggested 
for human beings (3.5 mgtkg). Methoxime is significantly 
more efficacious than obidoxime and pralidoxime, 
but its ED,, value is also higher than the dose 
suggested for human beingsn4 (14 mglkg). After 
intramuscular administration of cyclosarin in a sublethal 
dose (54 pglkg), the subsequent (after 30 s) antidotal 
therapy was more effective when HI-6 (100 p mollkg) 
was used, because reactivation of AChE in all 
body parts under study (frontal cortex, pontomedullar 
region, hypothalamus, hippocampus, basal ganglia 
and diaphragm) was more marked than in the case 
of obidoxime (100 p mollkg) as antidotal treatmentz2. 
When HI-6 was compared with obidoxime in eliminating 
of stressogenic effect of cyclosarin in rats, it was 
found that obidoxime had practically no effect, 
while HI-6 decreased plasma corticosteron level, 
and liver tyrosine aminotransferase activity increased 
after cyclosarin poisoning3z. 
Potentiostatic 
titration 
Potentiostatic 
titration 
Potentiostatic 
titration 
Potentiostatic 
titration 
3.2  In Vivo Reactivation in Mice 
(28.29) 
(28,29) 
(30) 
(27) 
Therapeutic efficacy of obidoxime and HI-6 in 
two doses (15 mglkg; 30 mglkg) was studied in 
mice intramuscularly intoxicated with cyclosarin. 
HI-6 was found to be better than obidoxime in both 
doses33. Also pralidoxime (50 mglkg) was compared 
in therapeutic efficacy with HI-6 (50 mglkg) in 
mice poisoned s.c. with cyclosarin. Both oximes 
were applied i.p. in combination with atropine (10 mglkg) 
and benactyzine (10 mglkg). The protective ratio 
of HI-6 was seven-fold higher than of pralidoximelZ. 
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3.3 In Vivo Reactivation in Guinea-pigs 
Anticonvulsant potency of some anticholinergic 
and benzodiazepine drugs was tested in guinea- 
pigs after intoxication with cyclosarin. Guinea- 
pigs were pretreated with pyridostigmine 
(0.026 mglkg i.m.) 30 min before cyclosarin 
(2  LD,,; 114 pglkg s.c.), followed 1 min later 
by pralidoxime (25 mglkg i.m.) and atropine 
( 2  mglkg i.m.). Anticholinergics (atropine,  
trihexyphenidyl, biperiden) o r  benzodiazepines 
(diazepam, midazolam) were administered i.m., 
5 min after seizure onset. All the drugs were 
capable of terminating seizure activity, with midazolam 
and trihexyphenidyl being significantly more potent 
than the other drugs, and midazolam being more 
rapid in controll ing seizure  than atropine,  
trihexyphenidyl or d i a ~ e p a m ' ~ . ' ~ .  
3.4 in Vivo Reactivation in Rhesus Monkeys 
The rhesus monkeys were challenged with 
SxLD,, cyclosarin (233 pglkg, i.m.) following 
pretreatment with pyridostigmine (0.3-0.7 mglkg 
per 24 h) and treated with atropine (0.4 mglkg, 
i.m.) and either 2-PAM (25.7 mglkg, i.m.) or HI-6 
(37.8 mglkg, i.m.) at the onset of clinical signs or 
at 1 min after exposure. 
The therapeutic regimen applied was completely 
effective against cyclosarin, saving all the 10 animals 
in each group. The cyclosarin-treated groups had 
minimal nervous system changes with no significant 
lesion difference resulting from the different oxime 
therapies in comparison with non-treated group in 
which neuronal degenerationlnecrosis and spinal 
cord hemmorrhage were observed9. When serum 
and biochemical changes were monitored, it was 
observed that the early release of serum enzymes 
which indicated damage to striated or cardiac muscles. 
There were mild elevations of sodium and potassium 
levels 2 days after exposure, inferring the presence 
of hypoxia, metabolic acidosis, slight plasma 
hyperosmolality, or a combination of these conditions. 
By 1 week after exposure, the initially elevated 
levels of creatine kinase, aspartate transaminase, 
lactate dehydrogenase, and alanine transaminase 
declined essentially to baseline levels, implying that 
injury to these tissues was not permanent36. 
4. THERAPEUTIC EFFICACY 
A combined regimen of prophylaxis and oxime 
therapy is now generally considered the most effective 
medical approach for dealing with the threat of 
nerve agent poisoning of military personnel3'. 
Pretreatment with carbamate ChE inhibitors such 
as pyridostigmine, shields a fraction of ChE in the 
periphery from irreversible inhibition by the nerve 
agents. However, pyridostigmine-induced increase 
in the level of ACh can itself cause symptoms of 
poisoning. Therefore, it would be useful to counteract 
the effects of the accumulated ACh using anticholinergic 
drugs such as benactyzine or trihexyphenidyl. In 
addition, the combination of pyridostigmine with 
anticholinergic drugs allows the dose of pyridostigmine 
that is otherwise limited by symptoms caused by 
elevated level of ACh to be increased and results 
in higher prophylactic efficacy than that observed 
for pyridostigmine alone3*. In the event of poisoning, 
immediate therapeutic treatment with an anticholinergic 
drug such as atropine sulphate, antagonizes the 
effect of excess ACh at muscarinic receptor sites, 
and an oxime is used to reactivate any unaged 
inhibited enzyme. The most important oximes are 
pralidoxime, obidoxime, methoxime, HI-6, and HL67. 
However, clinical experience has indicated that 
oximes are not always very efficient reactivators 
of AChE depending on the type of nerve agent 
intoxication. Therefore, none of these oximes can 
be regarded as a broad spectrum antidote, ie, effective 
against all the nerve agents39. The use of carbamate 
pretreatment in conjunction with atropine and oxime 
therapy has been shown to significantly increase 
the survival rate of experimental animals exposed 
to multiple LD,, doses of some organophosphate 
nerve  agent^^^.^'. 
This combined prophylaxis and oxime therapy 
regimen, however, does not appear to ameliorate 
nerve-agent induced, centrally mediated seizure 
activity and concomitant motor con~u l s ions~~ .  Seizure 
activity in organophosphate intoxication creates a 
problem for the medical management ofvexposed 
subjects. Additionally, the seizure activity rapidly 
progresses to status ep i lep t icu~ '~  and contributes 
to the profound brain damage and cardiac pathology, 
that develops as a consequence of exposure to 
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these highly toxic  compound^^^^^^. Therefore, 
concomitant administration of an adjunct compound 
selected for its anticonvulsant activity (eg diazepam) 
is required to improve the presently utilised regimen 
of carbamate pretreatment plus atropine and oxime 
therapy37. 
5. CONCLUSION 
The world political scene urges more detailed 
research on toxic organophosphate compounds and 
the development of treatment methods of their toxic 
effects. A comprehensive study on the treatment 
of cyclosarin toxicity has not been made. Kassa14 
reported that there is no single, broad-spectrum 
oxime suitable for the antidotal treatment of poisoning 
with all organobhosphate agents1" If more than 
one oxime is available, the choice depends primary 
on the identity of the responsible organophosphates. 
While the presently available oximes (pralidoxime, 
obidoxime) are not considered to be sufficiently 
effective against nerve agents1', especially in the 
case of soman poisoning5, the H oximes (HI-6, 
HLo7) appear to be very promising antidotes against 
nerve agents because they are able to protect 
experimental animals from toxic effects and improve 
survival of animals poisoned with supralethal doses". 
As a result, the effects of these reactivators in 
counteracting cyclosarin toxicity have to be examined. 
According to the latest in vitro studies, oximes 
HI-6, HS-6, BI-6, and KO33 seem to be promising 
because of their reactivation potency27.29.30,46. 
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